Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment.

ABSTRACT: Acute myeloid leukemia (AML) has high mortality rates, perhaps reflecting a lack of understanding of the molecular diversity in various subtypes and a lack of known actionable targets. There are currently 12 open clinical trials for AML using combination therapeutic modalities including all-trans retinoic acid (RA). Mutant nucleophosmin-1, proposed as a possible marker for RA response, is the criterion for recruiting patients in three active RA phase 3 clinical trials. We tested the ability of RA alone or in combination with either bosutinib (B) or 6-formylindolo(3,2-b) carbazole (F) to induce conversion of 12 de novo AML samples toward a more differentiated phenotype. We assessed levels of expression of cell surface markers associated with differentiation, aldehyde dehydroge

SUBMITTER: Bunaciu RP 

PROVIDER: S-EPMC5790527 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature